| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -24.2 | -15.0 |
| EPS (diluted, $ a share) | $-0.37 | $-0.38 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: IMRX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Immuneering Corp: key numbers
- Share price
- $3.52Close, Nov 16
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Immuneering Corp
All →Immuneering Leadership Change
Immuneering Corporation appointed Grant C. Bogle, MBA, to its Board of Directors as a Class III Director, effective November 9, 2026. Mr. Bogle will receive compensation under the company's standard non-employee director arrangements and has entered into a standard indemnification agreement.
- Counterparty
- Grant C. Bogle
Immuneering Financial Results
Immuneering reported Q3 2026 financial results and provided updates on its clinical pipeline, including the extension of follow-up for its Phase 2 pancreatic cancer trial as patients are living longer than projected. The company also announced that enrollment for its pivotal Phase 3 MAPKeeper 301 trial is ahead of schedule, allowing for an expanded enrollment target of 570 patients and a potential acceleration of the mid-2028 topline data readout.
“We are thrilled to share that follow-up in our Phase 2 trial in first-line pancreatic cancer is being extended because patients are living longer than projected. We now plan to provide an update on topline data from the atebimetinib + mGnP arm of that trial in the first half of 2027. We are also excited to report that enrollment in our pivotal Phase 3 MAPKeeper 301 trial is ahead of schedule. This strong momentum enables us to expand the enrollment target and potentially accelerate our expected mid-2028 topline data readout. We have updated our cash runway guidance to the fourth quarter of 2028 to reflect our Phase 2 extension, accelerated and expanded Phase 3 enrollment, and commercial readiness activities.”
Ben Zeskind, Ph.D., CEO of Immuneering